Sanofi acquired Cambridge-based Tidal Therapeutics for $160M upfront plus up to $310M in milestones (~$470M total), gaining Tidal's mRNA-based platform for in vivo immune cell reprogramming with applications in immuno-oncology and inflammatory diseases.
Key facts
AnnouncedApr 09, 2021
Deal value$470M
Deal typeAcquisition/Merger
Therapeutic areaOncology and immune diseases
IndicationsOncology and immune diseases
Key assetsmRNA in vivo immune cell reprogramming platform
MechanismmRNA-based nanoparticles for in vivo reprogramming of immune cells